Dr. Raymond Jacobson selected as director of the NIH Center for Scientific Review

The Center ensures NIH grant applications receive fair, independent, expert, and timely reviews. The institutional report frames the development in practical terms and ties it to the broader mission or observing effort.

It is relevant because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern. The gap between identifying a correlation in biological data and understanding the causal chain that produces it is routinely underestimated, and the history of biomedical research is populated with associations that collapsed when the mechanism was sought and not found. A result that comes with a proposed mechanism, even a partial one, is more useful than a purely descriptive finding because it generates testable predictions that can narrow the hypothesis space. Jacobson, Ph. D, as the director of NIH’s Center for Scientific Review (CSR), which ensures expert and fair review of the tens of thousands of grant applications received by the. Jacobson will continue strengthening NIH’s centralized peer review system so that we can continue backing the most scientifically meritorious research ideas in support of NIH’s.

His leadership will help ensure the first level of NIH review remains rigorous, fair, and transparent for all applicants. ” Prior to his selection, Dr. Jacobson helped guide NIH’s centralization of peer review, and as Acting Deputy Director of the NIH Office of Extramural Research in 2025, he advanced efforts to reduce.

Additionally, he was the director of the CSR Division of Receipt and Referral beginning in December 2024, where he led efforts to simplify application receipt and referral. Jacobson joined CSR in 2009 as a scientific review officer in the Bioengineering and Sciences Technologies Integrated Review Group (IRG).

During his postdoctoral training, he received a Miller Institute Fellowship, a highly competitive award supporting outstanding early-career scientists, and a Burroughs Wellcome. Their leadership during NIH’s transition to a centralized peer review system over the past year has effectively increased efficiency, competition, and transparency, while.

The broader interest lies in whether the reported effect points toward a real mechanism and not merely a reproducible but unexplained association. Biology has learned from decades of biomarker failures that correlation, even robust correlation, is not a substitute for mechanistic understanding. A pathway that can be traced from molecular interaction to cellular response to organismal phenotype provides a far stronger foundation for intervention than a statistical association discovered in a large dataset, however well the statistics are done.

About the NIH Center for Scientific Review (CSR): CSR organizes peer review groups that evaluate all grant applications, cooperative agreements, and research and development. Since 1946, CSR's mission has been to see that NIH grant applications receive fair, independent, expert, and timely reviews, free from inappropriate influences, so NIH can fund.

Because the account originates with NIH News Releases, it functions best as a primary institutional report that is close to the data and operations, not as independent scientific validation. Institutional communications are produced by organizations with legitimate interests in presenting their work in a favorable light, which does not make them unreliable but does make them partial. Details that complicate the narrative, including instrument limitations, unexpected failures and results below projections, tend to be minimized relative to progress messages. Technical documentation and peer-reviewed publications, where they exist, provide the complementary layer that institutional releases cannot substitute.

The next step is to test whether the effect repeats across different methods, cell types, model organisms and experimental conditions. Reproducibility is the first test, but mechanistic dissection is the second, and a result that passes both has a substantially better chance of translating into something clinically or biotechnologically useful. The path from a laboratory finding to an applied outcome typically takes a decade or more, and most findings do not complete it; the current result sits at the beginning of that process.

Source